Impact of Susceptibility to Placebo on the Effect of Transcranial Direct Current Stimulation (tDCS) in Fibromyalgia

Fibromyalgia Clinical Trial

— FIBROTEC  

Official title:

Impact of Susceptibility to Placebo on the Effect of Transcranial Direct Current Stimulation (tDCS) in Fibromyalgia: a Randomized Clinical Trial With Extended Home Stimulation

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05845528
• Other study ID #: 20200383
• Status: Active, not recruiting
• Phase: N/A
• Start date: September 16, 2021
• Est. completion date: November 20, 2023

Study information

• Verified date: April 2023
• Source: Hospital de Clinicas de Porto Alegre
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Fibromyalgia (FM) is a syndrome characterized by generalized musculoskeletal pain, fatigue, non-restorative sleep, cognitive changes, depressive and neurovegetative symptoms. It is known that conventional pharmacological therapies produce responses with little clinical impact in more than 50% of patients. Functional alterations of the motor cortex and its connections with subcortical structures have also been demonstrated in FM. Based on the above, the objective of this research is to identify subgroups of patients with greater potential for responsiveness to treatment with a view to advancing diagnosis and treatment. In this study, the therapeutic target will be transcranial direct current stimulation (tDCS) according to the potential of responsiveness to the placebo effect, with the precise location of the stimulation area by a neuronavigation system, with the objective of counter-regulating the dysfunctional processes responsible for triggering and maintaining FM symptoms. Therefore, this clinical trial aims to compare the efficacy of anodal tDCS applied to the left dorsolateral prefrontal cortex (DLPFC) compared to simulated tDCS in FM, according to susceptibility to placebo effect and serum endorphin levels.

Description:

This is clinical trial aims to compare the efficacy of anodal tDCS applied to the left dorsolateral prefrontal cortex (DLPFC) compared to simulated tDCS in FM, according to susceptibility to placebo effect and serum endorphin levels, in the following outcomes (1) treatment effectiveness, which includes daily measures recorded in an application by the Brief Pain Inventory (BPI), which allows pain assessment from a multidimensional perspective (pain intensity and interference in general activities, mood, mobility, work, personal relationships, sleep and enjoyment of life, etc.) (primary outcome). Secondary outcomes: the impact of pain on quality of life; levels of depressive symptoms; (2) Outcomes in psychophysical measures: pain threshold to electrical stimulation and heat; temporal summation to electrical stimulus; descending pain modulatory system function; (3) Identify predictors of response to the placebo effect through a hierarchical model with an analytical structure defined a 'priori', considering the hierarchical relationships between potential predictors such as: disability due to pain, catastrophism, depressive symptoms, psychiatric diagnoses, level of central sensitization, endorphin serum levels at baseline, drugs in use, etc. In this randomized, controlled, sham-controlled, parallel, double-blind clinical trial, 84 women with FM will be included, according to the criteria of the American College of Rheumatology (2016), aged between 18 and 70 years. Patients will be submitted to a simulated tDCS face-to-face session, mounted on the left DLPFC, and with a variation presented in the Numerical Verbal Pain Scale (NPS 0-10) equal to or greater than thirty percent of the baseline, the patient will be considered a high responder and below this low responder rate. This will be the criterion used to stratify randomization. They will receive 30 sessions of anodal tDCS lasting 20 min, with a current of 2 mA, applied to the left DLPFC at home. The location of the stimulation area will be done by a neuronavigation system. Patients will receive training in using the tDCS equipment.

They will have access to an instructional video on tDCS and a way of communicating with the team through Whatsapp. The follow-up time after the end of stimulation will be 12 weeks as recommended by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT). Patients should respond daily to BPI and possible side effects of tDCS. Home tDCS will be carried out with equipment developed by our research group, in partnership with Biomedical Engineering at Hospital de Clínicas de Porto Alegre (HCPA), with patent registration with the National Institute of Industrial Property (INPI) under number BR2020150164500. Our hypothesis is that active tDCS has a greater effect than simulated tDCS and that stimulation on the DLPFC has a greater impact in patients with greater responsiveness to the placebo effect on psychological symptoms, functional capacity for activities of daily living and inhibitory modulatory system function. descendant of pain. It is expected that the level of cortical disinhibition assessed by TMS measurements, as well as serum ß-endorphin levels, can serve as predictors of treatment response.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 100
• Est. completion date: November 20, 2023
• Est. primary completion date: April 25, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Women aged 18 to 65 years; who can read and write, with a confirmed diagnosis of FM according to the American College of Rheumatology criteria (2010-2016). Pain score equal to or greater than six on the Numerical Pain Scale (NPS 0-10) on most days of the last 3 months.

Exclusion Criteria:

• Residing outside the greater Porto Alegre area and pregnancy. Contraindications to TMS and tDCS: metallic implant in the brain; medical devices implanted in the brain, cardiac pacemakers; cochlear implant; history of alcohol or drug abuse in the last 6 months; neurological pathologies; hx of head trauma or neurosurgery; decompensated systemic diseases and chronic inflammatory diseases (lupus, rheumatoid arthritis, Reiter's syndrome); uncompensated hypothyroidism; personal history of cancer, past or undergoing treatment.

Related Conditions & MeSH terms

• Fibromyalgia
• Myofascial Pain Syndromes

Intervention

Device:
• s-tDCS
- Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
• a- tDCS
- Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it

Locations

Country	Name	City	State
Brazil	Hospital de Clinicas de Porto Alegre	Porto Alegre	Rio Grande Do Sul

Sponsors (1)

Lead Sponsor	Collaborator
Hospital de Clinicas de Porto Alegre

Country where clinical trial is conducted

Brazil, 

References & Publications (3)

Clauw DJ, Arnold LM, McCarberg BH; FibroCollaborative. The science of fibromyalgia. Mayo Clin Proc. 2011 Sep;86(9):907-11. doi: 10.4065/mcp.2011.0206. — View Citation

Keeser D, Meindl T, Bor J, Palm U, Pogarell O, Mulert C, Brunelin J, Moller HJ, Reiser M, Padberg F. Prefrontal transcranial direct current stimulation changes connectivity of resting-state networks during fMRI. J Neurosci. 2011 Oct 26;31(43):15284-93. doi: 10.1523/JNEUROSCI.0542-11.2011. — View Citation

Zanette SA, Dussan-Sarria JA, Souza A, Deitos A, Torres IL, Caumo W. Higher serum S100B and BDNF levels are correlated with a lower pressure-pain threshold in fibromyalgia. Mol Pain. 2014 Jul 8;10:46. doi: 10.1186/1744-8069-10-46. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	1.Change in pain level - first phase	Change from before and after the First phase of treatment on Pain scores assessed by a Numerical Pain Scale (NPS 0 to 10) (0 means no pain - 10 means the worst pain imaginable)	Time Frame: 1 month
Primary	Change in functional capacity - first phase	The Brief Pain Inventory (BPI) rapidly assesses the severity of pain and its impact on functioning	1 month
Secondary	Change in pain level - second phase	Change from before and after the Second phase of treatment on Pain scores assessed by a visual analogue scale (VAS 0 to 100mm) (0 means no pain - 100 means the worst pain imaginable)	3 months
Secondary	Change in functional capacity - second phase	Change from before and after the First phase of treatment on Total score on the Brazilian Profile of Chronic Pain: Screen (BPCP:S) (range from 0 to 93; high numbers means more pain severity, interference in daily activities and emotional burden)	3 months
Secondary	Change in Function of modulatory descending system	Change from before and after the First phase of treatment on the score in a numerical pain scale (NPS 0-10) for a moderate heat pain stimulus to the right arm (ventral region) during a conditioned pain modulation task (CPM-task), where participant keeps the counter-lateral hand in an iced cold water (0 to 1º Celsius)	1 month
Secondary	Change in Function of corticospinal pathway	Change from before and after the First phase of treatment on measures of motor threshold (MT), motor evoked potential (MEP), intracortical facilitation (ICF), short intracortical inhibition (SICI), and cortical silent period (CSP) assessed with transcranial magnetic stimulation (TMS).	Time Frame: 1 month
Secondary	7. Change in levels of Brain derived neurotrophic factor - BDNF	Blood samples will be collected at baseline and after the First phase of intervention in order to determine BDNF serum levels using a standardized kit	Time Frame: 1 month